12:00 AM
 | 
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Genz-112638: Phase III started

Genzyme began the double-blind, placebo-controlled Phase III ENGAGE trial to evaluate 50 or 100 mg GENZ-112638 given twice daily...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >